Less Frequent Brolucizumab Non-inferior to Standard Aflibercept for nAMD
Brolucizumab, which could be given every 12 weeks, showed non-inferior improvements in BCVA when compared with aflibercept every 8 weeks.
Intravitreal FA Insert Effectively Controls Uveitis Recurrences
Use of a 0.18 mg fluocinolone acetonide intravitreal insert effectively lowered the rate of uveitis recurrences and cumulative total recurrent episodes.
Paolo Silva, MD: Deep Learning Algorithm Predicts Future DR Severity
The algorithm identified PPL-HMA in 20% of eyes and was associated with a 2-3 fold increased risk of DR progression, development of PDR and receipt of intravitreal injections over 4 years.
Algorithm Detects Diabetic Retinopathy in Retinal Images with 97% Accuracy
The deep learning algorithm was tested on 71,000 images, and offers the potential to significantly increase the speed at which DR can be identified.
Outcomes Worse with Anti-VEGF than PRP in Patients Lost to Follow-Up
Eyes that received only anti-VEGF experienced significantly worse visual acuity from initial visit to final visit.
Artificial Intelligence Effectively Assesses Cell Therapy Functionality
A fully automated artificial intelligence-based system could effectively classify function and potency of cell therapy.
Jason Hsu, MD: Tackling Treatment Adherence in Patients with Diabetic Retinopathy
Anti-VEGF and pan-retinal photocoagulation can be effective, but neither are "one-and-done" therapies. Physicians must be proactive about how they handle patients with PDR.
Several Gene Therapies on Horizon for Retinitis Pigmentosa
A wave of novel gene therapies is on the horizon as treatments for patients with retinitis pigmentosa.
Paul Kaufman Hopeful, Inspired for Future of Glaucoma Research
The esteemed ophthalmologist spoke of novel therapies, importance of collaboration.
Paul Kaufman on Unmet Needs for Glaucoma, Burgeoning Solutions
In the second leg of a weighty interview, Kaufman ruminates on what more is needed.
Nikolas London Details Cross-Sectional Analysis of anti-VEGF Drugs
Study evaluated trials of aflibercept and ranibizumab in retinal vein occlusion.
At-Risk Drivers Can Be Identified by Visual, Cognitive Acuity
Medical tests more accurate than ticket history to identify crash risk.
New Baseline Models of DR Prediction Emerge at ARVO
Study helps modernize a 20-year-old testing model.
Study: Eating Fish Protects Against Diabetic Retinopathy in Asians
Strong correlation between fish intake and reduced severity of the disease.
Many With Diabetic Retinopathy Going Unscreened, Undiagnosed
The condition disproportionately affects minorities and the poor.
Paul Kaufman, MD, Speaks of His Motivations and Mission in Advance of Award and Lecture
The esteemed ophthalmologist was candid, thoughtful in deep interview with MD.
Aflibercept Vs. Ranibizumab: Similar QOL Benefits, Varied Costs for Treating Diabetic Macular Edema
Incremental ratio was too high even with most favorable scenario for aflibercept.
Quan Dong Nguyen on Pioneering Aflibercept, Ranibizumab, and Sirolimus
Nguyen has had the fortune of having been involved in the trials of all three.
Quan Dong Nguyen, MD, on Sirolimus's Potential to Change Uveitis Treatment
Nguyen speaks of the implications sirolimus could have if approved by the FDA.
Stanford's Quan Dong Nguyen, MD, Speaks on the SAKURA Trials
Researcher speaks on his team's findings regarding uveitis candidate sirolimus.
How Visual Acuity Affects Senior Motorists
Eye conditions help explain uptick in collisions.
“You can really change the life of a patient quickly,†Anat Loewenstein Discusses ARVO, Ophthalmology
"I’ve been going to ARVO for 20 years...every year I learn a lot,†Loewenstein says.
NIH's Jessica Mazerik Discusses Novel Competition to Grow Mini Retinas
$100,000 award for up to 3 winners in a race to grow the best artifical retinas.
Anat Loewenstein Talks ForeSeeHome, Unmet Needs in Retinal Disease
The biggest unmet need nowadays in retina disease is geographic atrophy..."
Anat Loewenstein Discusses UNRAVEL Trial of Ranibizumab and Aflibercept
It does show that there is a difference between the drugs,†she says.
NIH Offers Prize for Most Lifelike Retina Model
$1 million is up for grabs
Gestational Exposure to Marijuana Smoke May Impact Eye Function
Babies exposed to marijuana in the womb may require clinical care sooner.
Christine Birchwood Details the GiACTA Trial
Patients in tocilizumab treatment group 4 times more likely to see remission.
Christine Birchwood on the Significance of GiACTA
With many manifestations, giant cell arteritis must be addressed across specialties.
Lab-Grown Cells Could Restore Vision Loss
Retinal cell replacement counters effects of glaucoma in lab settings.